Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2009, Pages

  Winter Roach, Brett A ^a   Kitchener, Henry C ^b   Dickinson, Heather O ^c  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Antineoplastic agents *therapeutic use ; Carboplatin therapeutic use ; Chemotherapy, adjuvant methods ; Cisplatin therapeutic use ; Disease free survival; Early diagnosis; Female; Humans; Melphalan therapeutic use ; Neoplasm staging; Ovarian neoplasms *drug therapy; pathology; surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN; PLACEBO; RADIOISOTOPE;

ABDOMINAL HYSTERECTOMY; AREA UNDER THE CURVE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EPITHELIAL OVARIAN CANCER; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 70049109804     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004706.pub3     Document Type: Review

References (51)

1. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al.EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant Chemo-Therapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma:. Journal of the National Cancer Institute 2003;95(2):113-125 (Pubitemid 36193260)
2. Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, et al.Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Annals of Oncology 1995;6(9):887-893
3. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al.International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. Journal of the National Cancer Institute 2003;95(2):125-132 (Pubitemid 36193261)
4. Swart AC on behalf of ICON collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherpay for early stage ovarian cancer (ICON1). Journal of Clcinical Oncology 2007;25(18S):5509.
5. Trope C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al.Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Annals of Oncology 2000;11(3):281-288 (Pubitemid 30214664)
6. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al.Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. New England Journal of Medicine 1990;322(15):1021-1027
7. Chiara S, Conte P, Franzone P, Orsatti M, Bruzzone M, Rubagotti A, et al.High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. American Journal of Clinical Oncology 1994;17(1):72-76 (Pubitemid 24062739)
8. Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ, Levy D, Lagasse LD. The role of adjuvant therapy in Stage I ovarian cancer. American Journal of Obstetrics and Gynecology 1980;138(2):139-145 (Pubitemid 10001207)
9. Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, et al.Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. Journal of Clinical Oncology 1988;6(8):1254-1263 (Pubitemid 18196803)
10. Kojs Z, Glinski B, Reinfuss M, Pudelek J, Urbanski K, Kowalska T, et al.Results of a randomized prospective trial comparing postoperative abdominopelvic radiotherapy with postoperative chemotherapy in early ovarian cancer. Cancer Radiotherapie 2001;5(1):5-11.
11. Maggioni A, Benedetti Panici P, Dell'Anna T, Landoni F, Lissoni A, Pellegrino A, et al.Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. British Journal of Cancer 2006;95(6):699-704. (Pubitemid 44373484)
12. Sell A, Bertelsen K, Andersen JE, Stroyer I, Panduro J, Bentzen SM, et al.Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecologic Oncology 1990;37(3):367-373 (Pubitemid 20182983)
13. Sevelda P, Gitsch E, Dittrich C, Haider F, Czerwenka K, Schemper M, et al.Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II. Geburtshilfe Frauenheilkd 1987;47(3):179-185 (Pubitemid 17045023)
14. Sigurdsson K, Johnsson JE, Trope C. Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy. Annales Chirurgiae et Gynaecologiae 1982;71(6):321-329 (Pubitemid 13166824)
15. Smith JP, Rutledge FN, Delclos L, Mayer AR, Chambers SK, Graves E, et al.Results of chemotherapy as an adjunct to surgery in patients with localized ovarian cancer. Seminars in Oncology 1975;2(3):277-281
16. Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjorstad KE, et al.Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992;69(3):741-749
17. Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Seminars in Oncology 2000;27(3 Suppl 7):8-10.
18. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, et al.Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin - a gynecologic oncology group study. Journal of Clinical Oncology 2003;21(23):4350-4355 (Pubitemid 46621811)
19. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. British Journal of Cancer 1995;72:511-518
20. Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. CochraneD atabase of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001418]
21. Bell J, Brady MF, Young RC, Walker JL, Look KY, Rose GS, et al.Randomised phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2006;102(3):432-439 (Pubitemid 44353663)
22. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al.Carboplatin dosage: prospective evaluation of a simple formula based on renal function. Journal of Clinical Oncology 1989;13(8):2147-2148 (Pubitemid 19272848)
23. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor (s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2001.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-188
25. Elit L, Chambers A, Fyles A, Covens A, Carey M, Fung MF. Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer 2004;101(9):1926-1935 (Pubitemid 39425367)
26. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0. Lyon: IARC Press, 2004.
27. Green JA. Early ovarian cancer - time for a rethink on stage. Gynecologic Oncology 2003;90:235-237
28. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
29. Högberg T, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncologica 2001;40(2-3):340-360 (Pubitemid 32590833)
30. ICON collaborators. ICON2: randomised trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON. International Collaborative Neoplasm Study. Lancet 1998;352:1571-1576
31. ICON Collaborators. Paclitael plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin , and cisplatin in women with ovarian cancer: the ICON3 trial. Lancet 2002;360:505-515
32. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al.Cancer Statistics, 2008. CA: A Cancer Journal for Clinicians 2008;58:71-96.
33. Lyngstadaas A, Ekanger R, Hagen B, Himmelmann A, Iversen OE, Iversen T, et al.Primary treatment of ovarian cancer. Tidsskr Nor Laegeforen. 2005;125(3):278-281
34. Mayer AR, Chambers SK, Graves E, Holm C, Tseng PC, Nelson BE, et al.Ovarian cancer staging: does it require a gynecologic oncologist?. Gynecologic Oncology 1992;47:223-227 (Pubitemid 23001332)
35. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New England Journal of Medicine 1996;334(1):1-6. (Pubitemid 26012496)
36. Moher D, Pham D, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-613 (Pubitemid 28380142)
37. Morice P, Wicart-Poque F, Rey A, El-Hassan J, Pautier P, Lhomme C, et al.Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001;92:2412-2418 (Pubitemid 33029087)
38. National Cancer Institute. National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0). http://ctep.cancer. gov/reporting/ctc-v30.html.
39. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in five continents. Vol. VIII, Lyon: IARC Scientific Publication, 2002. [: No. 155]
40. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-2834 (Pubitemid 28562978)
41. Peto R. Statistical aspects of cancer trials. In: Halnan KE editor(s). Treatment of cancer. London: Chapman and Hall, 1982.
42. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al.EUROCARE-3: survival of cancer patients diagnosed 1990-1994- results and commentary. Annals of Oncology 2003;14:v61-v118. [: Supplement 5]
43. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al.Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecologic Oncology 2002;87(1):1-7.
44. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions ofmethodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412
45. Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96:889-892
46. Swart AC on behalf of ICONcollaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy in early stage ovarian cancer (ICON1). Journal of Clinical Oncology. Chicago: ASCO Annual Meeting Proceedings, 2007; Vol.25.
47. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al.International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute 2003;95(2):105-112 (Pubitemid 36196730)
48. Trope C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. Journal of Clinical Oncology 2007;25(20):2909-2920 (Pubitemid 47123155)
49. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Selvelda P, et al.Prognostic importance of degree of differentiation and cyst rupture in stage 1 invasive epithelial carcinoma. Lancet 2001;357:176-182 (Pubitemid 32108089)
50. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Torri V, et al.The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. Amultivariate analysis. Annals of Oncology 1998;9(10):1097-1101 (Pubitemid 28518148)
51. Winter-Roach B, Hooper L, Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. International Journal of Gynecological Cancer 2003;13(4):395-404. (Pubitemid 38220656)